Aptuit Adds Hot Melt Extrusion Technology To Its Integrated API And Formulation Development Expertise
GREENWICH, Connecticut, Dec. 17, 2014 /PRNewswire/ -- Aptuit LLC announces that it has recently invested in a twin screw extruder, Thermo Fisher 16, to exploit Hot Melt Extrusion Technology (HME), extending its range of technologies for processing poorly soluble drugs.
In making the announcement, Dr. Jonathan Goldman, CEO, Aptuit, explained, "The poor solubility of new chemical entities (NCEs) is one of the most frequent and greatest challenges to formulation scientists in the development of oral solid dosage forms. Now that we have added the new Thermo Fisher 16 extruder, Aptuit is in prime position to offer a suite of capabilities covering all technologies for increasing API bioavailability. Our addition of HME technology complements our existing micronization, wet bead nanomilling and spray drying capabilities."
HME has become an increasingly attractive technology in the pharmaceutical industry as it can offer:
- Enhanced dissolution and bioavailability of poorly soluble drugs
- Sustained drug release over an extended period of time
- Conversion of raw materials into a uniform shape and density enhancing formulation reproducibility
- Use in continuous wet granulation
Dr. Manuela Leone, EVP Operations, Aptuit, and General Manager of the Aptuit Center for Drug Discovery & Development in Verona, Italy, commented, "Our purchase of the Thermo Fisher 16 is in line with the Food and Drug Administration's (FDA) encouragement for drug-makers to use continuous manufacturing processes. It is a really exciting technology and complements our unique, integrated development solutions we provide to the industry."
For more information, please send an email to info@aptuit.com or contact:
Maria Garvey, Delfino Marketing at 914-747-1400 or maria@delfino.com
Lucio Da Ros, Aptuit at +39 0458218620 or lucio.daros@aptuit.com
Aptuit LLC provides the most complete set of integrated early discovery to mid-phase drug development services in the pharmaceutical industry including Drug Design & Discovery, Preclinical Biosciences, API Development and Manufacture, Solid State Chemistry, Pharmaceutical Sciences and Aptuit INDiGO® (a fixed-cost program that accelerates drug development). Fully integrated drug discovery & development services are available from a single site at The Aptuit Center for Drug Discovery & Development in Verona, Italy. The company maintains five global facilities with approximately 700 employees in Europe and the United States. Aptuit LLC is partnered with Welsh, Carson, Anderson & Stowe, one of the world's leading private equity investors.
For more information about Aptuit, visit www.aptuit.com
Share this article